Haku
Viitteet 1-1 / 1
Are products with an orphan designation for oncology indications different from products for other rare indications? : A retrospective analysis of European orphan designations granted between 2002-2012
(BioMed Central, 2017-02-16)
Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare ...